Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hematological malignancies (leukemia/lymphoma) at high risk or potential risk for tumor lysis syndrome. High risk: hyperuricemia of malignancy (Uric acid levels \>7.5); diagnosis of very aggressive lymphoma/leukemia based on Revised European-American Lymphoma (REAL) classification; acute myeloid leukemia, chronic myelocytic leukemia (CML) in blast crisis; high grade myelodysplastic syndrome only if they have \>10% bone marrow blast involvement and given aggressive treatment similar to acute myeloid leukemia (AML) (continued on #2)~2. (continued from # 1) Potential risk: diagnosis of aggressive lymphoma/leukemia based on (REAL) classification. Plus one or more of the following criteria: lactate dehydrogenase (LDH) \>/= 2 x upper limit of normal (ULN); Stage III-IV disease; Stage I-II disease with at least 1 lymph node/tumor \>5cm in diameter.~3. ECOG performance status 0-3~4. Life expectancy \>3 months~5. Negative pregnancy test (females of child bearing potential) within \</=2 weeks of rasburicase dose and use of efficient contraceptive method (both males and females). Pregnancy test may be performed on serum (HCG) or urine (HCG)~6. Signed written informed consent (approved by the Institutional Review Board/Ethics Committee) obtained prior to study entry~Exclusion Criteria:~1. Patient receiving any investigational drug for hyperuricemia within 30 days of planned first treatment with rasburicase~2. Pregnancy or lactation~3. Known history of significant allergy problem or documented history of asthma or asthmatic bronchitis~4. Known history of glucose-6-phosphate dehydrogenase deficiency~5. Known history of hemolysis and methemoglobinemia~6. Previous therapy with urate oxidase~7. Other conditions unsuitable for participation in the trial in the Investigator's opinion~8. Unwillingness to comply with the requirements of the protocol~9. Use of allopurinol within 72 hours of the study entry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
- Group B (Type: EXPERIMENTAL): Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).